{"schema_version":"secwatch.filing_event.v1","accession":"0001703057-26-000049","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2026-08-07T20:43:59+00:00","discovered_at":"2026-08-07T20:45:00.372420+00:00","generated_at":"2026-08-07T20:45:05.763596+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"AbCellera to release Phase 2 top-line data for ABCL635 (menopause VMS) on Aug 10, 2026","bullets":["Top-line data from Phase 2 trial of ABCL635 for moderate-to-severe vasomotor symptoms due to menopause to be released before market open on Monday, August 10, 2026.","Investor conference call and webcast scheduled at 4:30 a.m. PT / 7:30 a.m. ET on the same day.","No trial results disclosed in this announcement; data release is upcoming catalyst."],"urls":{"canonical":"https://secwatch.observer/filing/0001703057-26-000049","json":"https://secwatch.observer/filing/0001703057-26-000049.json","markdown":"https://secwatch.observer/filing/0001703057-26-000049.md","text":"https://secwatch.observer/filing/0001703057-26-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000049/0001703057-26-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000049/abcl-20260807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-07T20:45:05.763596+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}